Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neopath (NPTH) -- Ignore unavailable to you. Want to Upgrade?

To: Sigmund who wrote (138)	5/8/1998 12:51:00 PM
From: Joseph Ziebarth	Read Replies (1) \| Respond to of 178

" remove Nelson and bring in someone who knows how to run a company. " I'm not sure what you see as poor management, but let me say that Nelson sure knows how to recruit engineers that can creatively put tools to other tasks than originally designed. You will see a number of spin-off applications to this artificial intelligence that is being used for Auto-pap. Some of the off the shelf ideas being shared over coffee are really exciting. My engineer friend just smiles and say's "no comment, but just wait." I've known him since long before he went to this company and there isn't a more competent and creative experimenter in the Puget Sound area. Shape recognition is really a great tool to speculate on other applications.

To: Sigmund who wrote (138)	5/8/1998 3:00:00 PM
From: Cytotekk	Read Replies (1) \| Respond to of 178

That site is a Yahoo business and finance site. Go to business and finance and type in npth. The most recent news is first. The is no preferential treatment for cytotechs, they meet competency standards or they are out of a job. No one is ever assigned pap smears because they are most likely to be bad or good. May I say that competency can be defined by the minimum skills required for the job. The QC rules for rescreening are to insure that most misses are picked up by your best techs. All misses are documented and after so many misses, it is good-bye. We even have to go and resceen 500-5000 slides once we find a tech missing high grades, it is called retrospective screening. Sometimes a mediocre tech will refer a slide because they are unsure of what they are looking at, that is when someone like me makes a judgement of negative or atypia and then passes the slide onto a pathologist who may or may not be competent in cytology. The ones who are marginal or incompetent will rely on the good techs to rescreen the techs they do not know or do not trust and then they OK what the lead tech says. Sigmund, regardless of what the public thinks of us health care workers, most of us care about patients,I went into this to help women, not make good money. For your information, if indeed the ruling requires 15% rescreen, that is what is going on now in most labs anyway. So you still get a 25% signout rate=1 cytotech even with a 15% rescreen rate. I here that papnet, NSIX, is going for primary screening, what a joke, is everyone going to send all their slides out for the primary screening? Autopap stays on site at each individual lab. Yes, things look good, but with all the anti-technology pathologists and tech publishing, stock price increase may be very gradual. I just hope the lab managers and risk managers see the obvious logic to this system and override the reluctant anti technology forces in Cytology.